Measuring tibial cortical bone status by ultrasonic velocity

BACKGROUND

Post-menopausal osteoporosis has become a serious public health problem with the increase of the geriatric population. Dual energy x-ray absorptiometry (DEXA) is the most common method for diagnosis of osteoporosis by quantitative change of bone, but recently there is increasing interest in measuring both qualitative and quantitative changes of bone by ultrasound. This study measured ultrasound velocity of anterior tibial cortex to evaluate the feasibility of detecting cortical bone status by speed of sound (SOS).

METHODS

SOS in anterior tibial cortex was measured on 205 females referred from clinicians for routine bone mineral density (BMD) measurement. These females were divided into 2 groups. Group 1 consisted of 170 females aged from 30 to 75 years (mean: 55.2 +/- 9.3 years), who never received estrogen therapy. Group 2 consisted of 35 females in the post-menopausal status aged ranged from 45 to 69 years (mean: 51.5 +/- 3.5 years), who had received estrogen gel or oral estrogen tablet (0.625 mg/day) replacement therapy for prevention of postmenopausal osteoporosis for a period of 6 to 68 months (mean: 25.3 +/- 2.3 months). For precision test, 3 volunteers whose SOS was measured by 2 different operators were also enrolled in our study. BMD by DEXA of L-spine and/or hip was also performed on the same day of SOS examination. We analyzed the precision of this new method, calculated mean value of SOS to see if there was any difference with respect to pre- at, and post-menopausal status between estrogen users and nonusers by SOS, and tried to find the relationship of SOS with body habitus and BMD.

RESULTS

Mean value of SOS of group 1 females was 3852 +/- 150.3 m/s, with peak value in the fourth decade. There were inverse correlation of SOS with age (r = -0.36, p < 0.0005) and the period after menopause (r = -0.32, p < 0.0005). The decreasing rate of SOS per decade from 31 to 50 years of age was 1.7%, while that of 51 to 70 years was 4.3% in group 1 females. With regard to menopausal status, there was significant difference of SOS between pre- and post-menopausal females (p = 0.01, ANOVA test), between at and post-menopausal females (p = 0.02). Significant difference (p < 0.05, ANOVA test) between group 2 estrogen users and group 1 postmenopausal nonusers was also noted. There was no evidence of correlation of body weight or height with SOS. Both inter- and intra-operator precision of SOS was under or equal to 0.32%. Moderately correlation between SOS and BMD was noted.

CONCLUSIONS

Our study demonstrated good precision in SOS measurement of tibial cortical status. It was inversely correlated with age and post-menopausal period; it also significantly discriminated estrogen users from nonusers, and pre-, at from post-menopausal subgroups. However, for further evaluation of the relationship between SOS and the most severe complication of osteoporosis, i.e. osteoporotic fracture, population-based long-term followup is still required.

Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen

We examined the full-length hepatitis B virus (HBV) envelope (surface antigen or HBV small surface antigen [HBsAg]) sequences of 12 different liver samples from 10 different hepatoma-containing chronic carriers. Surprisingly, novel and frequent mutations occurred predominantly at amino acids 40 and 47 of HBsAg, in addition to within a known protective B-cell epitope (so-called group a determinant of HBsAg 124-148). Approximately 58% of chronic carriers contain mutations at the group a determinant. The mutation frequency at the hotspot codons 40 and 47 is approximately 83%, 1 order of magnitude higher than at the known polymorphic sites of subtype-specific determinants at codons 122 and 160, which is approximately 4%. This new mutational domain is found to coincide with a major histocompatibility complex class I-restricted T-cell epitope. The potential biological significance of this novel mutation in the immunopathogenesis of HBV chronic carriers is discussed.

Metabolism and disposition of the antifolate LY231514 in mice and dogs

The metabolism and disposition of LY231514 was studied in mice and dogs. LY231514 is a novel pyrrotopyrimidine-based multi-target antifolate (MTA) showing broad in vivo antitumor activity in mouse models and is currently in phase II human clinical trials. Doses (iv) of the compound showed high plasma levels, resulting in AUC values of 30-33 micrograms-hr/ml for mice and dogs after 20 and 7.5 mg/kg doses, respectively. The compound was eliminated rapidly. Half-life values for mice and dogs were about 7 and 2 hr, respectively. In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans. Fecal elimination was the major excretion pathway in mice after single iv doses of [14C]LY231514. Urine constituted the major route of excretion in dogs. Parent LY231514 accounted for the majority of urinary radiocarbon in mice (90%) and dogs (68%). Minor metabolites were found in urine, but the amounts were too small to isolate or identify. Based on an earlier observation that LY231514 photodegraded to produce reaction products having similar retention times as these minor urinary isolates, a photo-oxidation system was developed which in fact produced these metabolites. Subsequently, these photolytically-produced materials were used as standards to identify two novel in vivo metabolites formed by oxidation of the pyrrolo-pyrimidine ring system of LY231514. The oxidative transformations are similar to those observed for tryptophan and other indoles in that the pyrrole ring is oxidized to give an amide; further oxidation cleaves this ring, one ring carbon is lost, and a ketone is formed.

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl ]-benzoyl]-L-glutamic acid (LY231514) is a novel pyrrolo[2,3-d]pyrimidine-based antifolate currently undergoing extensive Phase II clinical trials. Previous studies have established that LY231514 and its synthetic gamma-polyglutamates (glu3 and glu5) exert potent inhibition against thymidylate synthase (TS). We now report that LY231514 and its polyglutamates also markedly inhibit other key folate-requiring enzymes, including dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). For example, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibition against TS, DHFR, and GARFT, respectively. In contrast, although a similar high level of inhibitory potency was observed for the parent monoglutamate against DHFR (7.0 nM), the inhibition constants (Ki) for the parent monoglutamate are significantly weaker for TS (109 nM) and GARFT (9,300 nM). The effects of LY231514 and its polyglutamates on aminoimidazole carboxamide ribonucleotide formyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase were also evaluated. The end product reversal studies conducted in human cell lines further support the concept that multiple enzyme-inhibitory mechanisms are involved in cytotoxicity. The reversal pattern of LY231514 suggests that although TS may be a major site of action for LY231514 at concentrations near the IC50, higher concentrations can lead to inhibition of DHFR and/or other enzymes along the purine de novo pathway. Studies with mutant cell lines demonstrated that LY231514 requires polyglutamation and transport via the reduced folate carrier for cytotoxic potency. Therefore, our data suggest that LY231514 is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multiple inhibition of several key folate-requiring enzymes via its polyglutamated metabolites.

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

PURPOSE

Cell cycle-related events in CCRF-CEM lymphocytic leukemia cells were examined subsequent to inhibition of thymidylate synthase (TS) or GAR formyltransferase (GARFT) and prior to cell death or stasis.

METHODS

Cell populations were treated with the GARFT inhibitors 6R-5, 10-dideazatetrahydrofolate (Lometrexol) or LY309887, the TS inhibitor ZD1694, or the multitargeted antifolate LY231514. DNA content, nucleoside precursor incorporation and proliferating cell nuclear antigen (PCNA) expression as functions of drug treatment were assessed by multiparameter flow cytometry. Cellular respiration was measured by MTT analysis and apoptosis was detected by extraction of DNA fragments.

RESULTS

Cell populations treated for up to 96h with lometrexol or LY309887 did not replicate and maintained a cell cycle distribution with distinct G1, S and G2/M regions. The number of S phase cells in treated populations was slightly elevated relative to control as measured by DNA content and PCNA. However, these cells were unable to incorporate 5-bromodeoxyuridine (BrdU). Throughout treatment, cells incubated with GARFT inhibitors maintained intact membranes and respired at a level comparable to untreated cells. In contrast, ZD1694 as well as LY231514, induced synchronization of the treatment population at the G1/S interface within 12h of drug addition. This was followed by synchronous entry of the population into S phase. After 24 h of treatment, more than 90% of the cells were capable of incorporating BrdU and stained positive for PCNA. DNA fragmentation occurred in cells treated with ZD1694 or LY231514 but not in those treated with GARFT inhibitors. In addition, the viable cells remaining after 24-48 h of treatment with ZD1694 or LY231514 were respiring at twice the level of untreated cells.

CONCLUSION

These results demonstrate that the distinct endpoints of GARFT and TS inhibition are preceded by distinct cell cycle and metabolic alterations.

Neurogenic substance P stimulates osteogenesis in vitro

Previous studies have shown that there is colocalization of substance P (SP) and calcitonin gene-related peptide (CGRP) immunoreactive nerve fibers in bone, periosteum and bone marrow. Because SP may also possibly play a role in bone formation, we decided to test whether it has an osteogenic stimulating effect on developing bone in vitro. To this end, 0.4, 4 and 40 micrograms/ml of SP in BGJb medium was added daily to 3 million light density (LD) bone marrow white cells which were separated by Ficoll-Paque density gradient separation then seeded onto a previously prepared fibroblast feeder layer in Petri dishes. Seven days after adding SP, in the control without SP there were 2 bone colonies; with 0.4 micrograms of SP there were 3 colonies; with 4 micrograms there were 5 colonies; with 40 micrograms there were 7 colonies. In addition, there was an increase in the size of bone colonies in the SP-added group. The results indicated that SP had a dose-related osteogenic stimulating effect. The increase in the number and size of bone colonies by SP was probably caused by stimulating stem cell mitosis, osteoprogenitor cell differentiation or osteoblastic activity.

Calcitonin gene related peptide enhances bone colony development in vitro

Recent evidence suggests that sensory nerve fibers of the dental pulp secrete calcitonin gene related peptide alpha exactly where secondary or tertiary dentin is mineralized. In addition, calcitonin gene related peptide raises the level of cyclic adenosine monophosphate in osteoblasts, indicating a potential effect on secretory activity in bone. Because calcitonin and calcitonin gene related peptide are formed from the same gene, the authors tested whether calcitonin gene related peptide or calcitonin has an osteogenic potential in vitro. To this end, 0.01, 0.1, and 1 microg/ml of salmon calcitonin or rat calcitonin gene related peptide in Bigger, Gwatkin, Jackson b medium was added daily to 3 x 10(6) rat light density bone marrow leukocytes that were separated with the Ficoll-Paque density gradient separation method, then seeded on a previously prepared fibroblast layer in Petri dishes. After 7 days, the number and size of bone colonies formed in the calcitonin gene related peptide (0.1 or 1 microg/ml) added group was significantly greater than that of the control group. There was no statistically significant difference between the calcitonin added and control groups. Calcitonin gene related peptide has an osteogenic stimulating effect, either by stimulating stem cell mitosis or osteoprogenitor cell differentiation (or both), whereas salmon calcitonin has no effect.

Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts

The importance of polyglutamation for the activation of natural folates and classical antifolates and recent evidence for the role of dietary folate as a biochemical modulator of antifolate efficacy led us to investigate the influence of changes in dietary folate on folylpolyglutamate synthetase (FPGS) activity. Activities were measured using lometrexol (6R-5,10-dideazatetrahydrofolic acid) as a substrate for FPGS with extracts of murine tissues, murine tumors, and human tumor xenografts from mice on standard diet or low folate diet. Tissues and tumors from mice on standard diet exhibited a 6-fold range of FPGS activity. Kidney had the lowest activity (36 pmol/hr.mg protein), followed by the human xenograft PANC-1 pancreatic carcinoma (46 pmol/hr.mg protein), liver (109 pmol/hr.mg protein), murine C3H mammary tumor (112 pmol/hr.mg protein), and the human xenograft MX-1 mammary carcinoma (224 pmol/hr.mg protein). In response to restricted dietary folate, four out of five tissues had significantly increased (25-50%) FPGS activity. Only the tumor with highest FPGS activity under standard diet conditions (MX-1 mammary) did not respond to low folate diet. The results indicate that changes in dietary folate intake can modulate FPGS activity significantly in vivo and suggest that the tissue distribution and toxicities of classical antifolates requiring polyglutamation for activation and cellular retention will be influenced significantly by folate status of the host.

MR imaging of articular cartilage in the ankle: comparison of available imaging sequences and methods of measurement in cadavers

OBJECTIVE

To assess hyaline cartilage of cadaveric ankles using different magnetic resonance (MR) imaging techniques and various methods of measurement.

DESIGN AND PATIENTS

Cartilage thicknesses of the talus and tibia were measured in ten cadaveric ankles by naked eye and by digitized image analysis from MR images of fat-suppressed T1-weighted gradient recalled (FS-SPGR), sequences and pulsed transfer saturation sequences with (FS-STS) and without fat-suppression (STS); these measurements were compared with those derived from direct inspection of cadaveric sections. The accuracy and precision errors were evaluated statistically for each imaging technique as well as measuring method. Contrast-to-noise ratios of cartilage versus joint fluid and marrow were compared for each of the imaging sequences.

RESULTS

Statistically, measurements from FS-SPGR images were associated with the smallest estimation error. Precision error of measurements derived from digitized image analysis was found to be smaller than that derived from naked eye measurements. Cartilage thickness measurements in images from STS and FS-STS sequences revealed larger errors in both accuracy and precision. Inter-observer variance was larger in naked eye assessment of the cartilage. Contrast-to-noise ratio of cartilage versus joint fluid and marrow was higher with FS-SPGR than with FS-STS or STS sequences.

CONCLUSION

Of the sequences and measurement techniques studied, the FS-SPGR sequence combined with the use of digitized image analysis provides the most accurate method for the assessment of ankle hyaline cartilage.

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol

Lometrexol, a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically. Unexpected observations of delayed cumulative toxicity prompted a search for a second generation antimetabolite with a more favorable biochemical, pharmacological and toxicological profile. LY309887, 6R-2',5'-thienyl-5, 10-dideazatetrahydrofolic acid, had 9-fold greater potency to inhibit GARFT (Ki = 6.5 nM) compared to lometrexol. Like lometrexol, LY309887 was activated by folpolyglutamate synthetase, however, it had a lower first order rate constant. In vitro and in vivo data were consistent with these observations: polyglutamation of LY309887 was less extensive compared to lometrexol and livers of mice accumulated fewer polyglutamates of LY309887 than polyglutamates of lometrexol. The affinities of these two compounds for isoforms of human folate receptors (FR) were compared. Lometrexol had a 6-fold higher affinity for FR alpha than LY309887 and both compounds had higher affinity for the alpha isoform compared to the beta isoform. The selectivity of LY309887 for FR alpha (beta (Ki)/ alpha (Ki) = 10.5) was twice that of lometrexol's (beta / alpha = 5.0). Lometrexol and LY309887 were potent cytotoxic compounds against the human leukemia cell line CCRF-CEM with IC50's of 2.9 nM and 9.9 nM, respectively. In vivo, LY309887 was more potent than lometrexol at inhibiting tumor growth in the C3H mammary murine tumor model and several tumor xenografts. Excellent efficacy was achieved by both compounds in several colon xenografts. In two pancreatic human xenografts, LY309887 achieved greater efficacy than lometrexol. In summary, the biochemical and pharmacological properties of lometrexol and LY309887 support the hypothesis that these antifolates will have clinical activity against human solid tumors. LY309887 is a second generation GARFT inhibitor with biochemical and pharmacological properties which distinguish it from lometrexol and suggest that it will have broad antitumor activity, a different pharmacokinetic profile and produce less toxicity than lometrexol in cancer patients.

Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression

Membrane-associated folate receptors (FRs) have been detected in many mammalian species, and multiple isoforms have been identified. The pharmacological properties of FRs from murine kidney, liver, and six murine tumors were characterized. Murine kidney expressed primarily folate-binding protein 1, analogous to human FR-alpha, whereas murine liver expressed predominantly folate-binding protein 2, analogous to human FR-beta. Five of six murine tumors expressed high-affinity FRs with pharmacological properties consistent with folate-binding protein 1 isoform expression. Restriction of dietary folate resulted in significant changes in the FR expression in most murine tissues. Kidney and tumor FRs showed a decreased affinity for folic acid, suggesting a change in isoform expression in response to a low folate diet. Density of the FR in the kidney decreased, and, in contrast, density of the FR in all tumors increased. The response of the liver to a low folate diet was unique in that there were no detectable changes in affinity or density of liver FR. Changes in dietary folate that modulate FR isoform expression may have relevance for cancer patients treated with antifolates.

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid

Recent clinical trials with lometrexol [(6R)-5,10-dideazatetrahydrofolate] have revealed a level of toxicity in humans that was not predicted on the basis of previous in vivo preclinical studies. Because standard laboratory animal diets contain high levels of folic acid relative to human folate intake, the toxicity and therapeutic activity of lometrexol was studied in mice under conditions of restricted dietary folate intake. Remarkably, the lethality of this drug increased by three orders of magnitude in mildly folate-deficient mice, mimicking the unexpected toxicity seen in humans. Lometrexol had limited therapeutic activity in folate-deficient mice bearing the C3H mammary adenocarcinoma, compared with the substantial therapeutic index for treatment of this tumor in animals on standard diet. When folic acid was administered p.o. to mice that were mildly folate deficient, antitumor activity was again observed at nontoxic doses of lometrexol, and the range of lometrexol doses that allowed safe therapeutic use of this drug increased at higher dietary folate intake. At a fixed dose of lometrexol, the antitumor effects in animals were dependent on the level of dietary folate and went through a distinct optimum. Excessively high folate intake reversed the antitumor effects of lometrexol. Optimization of the folic acid content in the diet and of the lometrexol dosage are predicted to have substantial impact on the clinical activity of this class of drugs.

Peripheral blood mononuclear cells develop into multinucleated osteoclasts in tissue culture

BACKGROUND

Previous studies have shown that osteoclasts are derived from mononuclear cells of hemopoietic bone marrow and peripheral blood. The purpose of this study was to demonstrate the presence of multinucleated osteoclasts after adding mononuclear cells from peripheral blood into established explants of fetal mouse calvaria in vitro.

METHODS

In order to utilize osteoclast-free bone, the fetal calvariae were obtained from 13-14-day pregnant Swiss Webster mice and cultured in BGJb medium for 9 days. At day 9, peripheral blood mononuclear cells were isolated as a light density layer from adult Swiss Webster mice with the Ficoll-Paque density gradient separation method and co-cultured with the osteoclast-free, fetal mouse calvaria.

RESULTS

After 10 days of co-culture, multinucleated cells, which have all the characteristics of osteoclasts, were found in juxtaposition to seams of woven bone. Two multinucleated osteoclasts per one million light density peripheral blood mononuclear cells were found in the experimental group; none were found in the mononuclear cell-free control group.

CONCLUSIONS

Peripheral blood mononuclear cells can give rise to multinucleated osteoclasts in developing bone in vitro but will not develop without bone.

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs

Wortmannin, a fungal metabolite, was identified as a potent inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI 3-kinase). Due to the importance of PI 3-kinase in several intracellular signaling pathways, structure-activities studies on wortmannin analogs were performed in an effort to understand the structural requirements necessary for PI 3-kinase inhibition. Since wortmannin is an irreversible inhibitor of PI 3-kinase, it was postulated that covalent attachment at the electrophilic C-21 site was a possible mode of action for PI 3-kinase inhibition. We have prepared various wortmannin analogs which address the possibility of this mechanism. Of particular interest are compounds which affect the C-21 position of wortaminnin either sterically or electronically. Our results support the conclusion that nucleophilic addition by the kinase onto the C-21 position of wortmannin is required for inhibition of PI 3-kinase by wortmannin analogs. Additionally, we have prepared several D-ring analogs of wortmannin, and their activities are reported herein. We conclude that the wortmannin D ring is an important recognition site since modifications have such a dramatic effect on inhibitor potency. Finally, the identification of 17beta-hydroxywortmannin represents the first reported subnanomolar inhibitor of PI 3-kinase. These studies, along with in vivo antitumor experiments, suggest that the mechanism of PI 3-kinase inhibition correlates to the associated toxicity observed with wortmannin-based inhibitors of PI 3-kinase.

Interleukin-1 alpha stimulates osteoclast formation from peripheral blood monocytes and increases osteoclastic activity

BACKGROUND

Interleukin-1 (IL-1) is produced by monocytes and marrow stromal cells and can stimulate bone resorption in tissue culture. In addition, IL-1 can induce osteoclast-like cell formation in long-term bone marrow culture. However, whether IL-1 can increase osteoclast formation by stimulating fusion of peripheral blood monocytes is not clear. In addition, the precise effect of IL-1 on osteoclastic activity is still not well known.

METHODS

Using the bioassay of osteoclast formation, osteoclast-free fetal calvariae were harvested from 14-day timed-pregnant Sprague-Dawley rats and cultured in BGJb medium for 10 days. On the 10th day, mononuclear cells were obtained from peripheral blood of 8-week-old female Sprague-Dawley rats through cardiac puncture and Ficoll-Paque density gradient separation method and co-cultured with osteoclast-free developing bone explant. On the same day, various concentrations of IL-1 alpha (1,10 or 100 U/ml) were added daily in the experimental dishes while only BGJb medium was added in the controls. In addition, 45Ca release assay and quantitation of nuclei per osteoclast were performed to evaluate the effect of IL-1 alpha on osteoclastic activity.

RESULTS

Ten days after adding monocytes, there were 14.25 osteoclasts in the control, without IL-1 alpha; with 1 U of IL-1 alpha, there were 14.75 osteoclasts; with 10 U of IL-1 alpha, there were 18.00 osteoclasts; with 100 U of IL-1 alpha, there were 20.75 osteoclasts. In addition, IL-1 alpha stimulated the release of 45Ca and increased the number of average nuclei per osteoclast dose-dependently, indicating a significant increase in bone resorption.

CONCLUSIONS

IL-1 alpha could increase osteoclast formation by stimulating the fusion of peripheral blood monocytes. In addition, IL-1 alpha is a potent stimulator of osteoclastic activity.

The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol

We have studied the molecular effects of a LFD in a murine model in order to better define the biochemical changes associated with folate deficiency. In addition, we have demonstrated the effect of a LFD on the pharmacokinetic profile and therapeutic activity and toxicity of lometrexol. These studies showed increased density of FR in tumors implanted in LFD mice and a decrease in the affinity of these receptors for folic acid. The results suggest that tumors can compensate for low folate bioavailability by up-regulation of a second FR with slightly lower affinity for folic acid. The higher density of this FR would provide greater capacity for garnering serum folate. FPGS activity increased in several tumors and liver and kidney of LFD mice. The increase in this enzyme activity would result in enhanced polyglutamation of folates and classical antifolates and thus increased cellular retention. Consistent with these changes in liver FPGS, mice injected i.v. with a single dose of lometrexol accumulated significantly more drug in liver and tumors of LFD animals compared to SD mice. Also, higher liver concentrations of lometrexol persisted longer in LFD mice. Polyglutamate analysis showed that longer polyglutamate forms appeared earlier in liver of LFD mice. After 7 days, longer polyglutamyl forms were recovered from liver of LFD mice (octa- and hepta-glutamyl lometrexol) compared to those on SD. A comparison of the efficacy and toxicity of lometrexol in C3H mammary tumor-bearing mice showed that in mice on LFD, lometrexol treatment produced a delayed toxicity with an LD50 of 0.1-0.3 mg/kg, a 3000-fold increase in lethality compared to SD mice. Supplementation of mice with folic acid restored anti-tumor activity and increased the therapeutic dose-range over which efficacy could be assessed. These studies support the use of folic acid supplementation for cancer patients treated with antifolate therapy in order to prevent the biochemical changes in FR and FPGS associated with folate deficiency, prevent delayed toxicity to GARFT inhibitors and enhance the therapeutic potential of this class of drugs.

Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2

The RAG1 and RAG2 gene products are indispensable for activating somatic rearrangement of antigen receptor gene segments. The two proteins form a stable complex in primary thymocytes as well as when expressed in adherent cells. In both cell types, most cells localize RAG proteins at the periphery of the nucleus. However, when overexpressed in fibroblast cells, RAG1 is found largely in the nucleolus. Nucleolar localization of RAG1 is mediated by several domains containing stretches of basic amino acids, indicating that RAG1 has affinity for RNA or ssDNA. The RAG1 interacting proteins SRP1 and Rch1 directly bind to the nuclear localization signals of RAG1, which mediate the nuclear and nucleolar translocation of the protein. RAG1 appears to have a binary structure, each half containing multiple regions that can act as NLSs, binding sites for the SRP1/Rch1 family, and RNA binding domains.

A graphical method for the determination of the mode of hydrolysis of biodegradable polymers

PURPOSE

To develop a qualitative method for the determination of the mode of scission in the hydrolysis of biodegradable polymers.

METHODS

The method requires determination of the molar fraction of monomer (m1) by 1HNMR or HPLC, and the degree of polymer degradation (alpha) determined by 1HNMR.

RESULTS

If the scission of the backbone bonds is completely random, the molar fraction of the monomer must equal the square of the degree of degradation as predicted by Kuhn (1). If the degradation follows an exclusive chain-end "unzipping" mechanism then, m1 = alpha. Experimental data falling on the theoretical curves (m1 vs. alpha) confirm the corresponding mode of scission. If the data fall between the two curves, it suggests a faster chain-end scission than random scission. When data fall below both of these curves, it suggests the chain-end bonds are less reactive than the internal bonds.

CONCLUSIONS

The acid catalyzed hydrolysis of a poly(ortho ester) and the base catalyzed hydrolysis of poly(D,L-lactide) (PLA) were by a random scission mechanism, while acid catalyzed hydrolysis of PLA demonstrated faster chain-end scission.

Calculation of hydrolytic rate constants of poly(ortho ester)s from molecular weights determined by gel permeation chromatography

PURPOSE

To obtained rate constants from weight-averaged (Mw) or z-averaged (Mz) molecular weights for polymers of Schule-Flory distribution and undergoing random scission. These constants were compared with those obtained by parallel 1HNMR studies.

METHODS

The hydrolysis of two poly(ortho ester)s were followed by 1HNMR and gel permeation chromatography (GPC).

RESULTS

Equations to convert number-averaged (Mn), Mw and Mz into fraction of backbone remaining (fc) were derived. First-order hydrolytic rate constants of two poly(ortho ester)s; DETOSU-HD and DETOSU-CDM were calculated using these relationships. The rate constants calculated from 1HNMR, Mz and Mw were 0.215, 0.21 and 0.182 hr-1, respectively, for DETOSU-CDM and 0.152, 0.086 and 0.038 hr-1 for DETOSU-HD. The large discrepancy in the rates determined by 1HNMR and GPC in the latter case was attributed to that the detector response (refractive index) of the monomers was lower than that of the high molecular weight polymer. The difference is small in the case of DETOSU-CDM, and the rates calculated from GPC data were comparable or nearly identical to that obtained from 1HNMR data.

CONCLUSIONS

Although GPC can yield rapid and valuable kinetic data for the degradation of biodegradable polymers, the system, however, must be carefully calibrated to account for the variations in Mark-Houwink coefficients and in the response of the mass detector between the high and low MW polymers.

Core antigen mutations of human hepatitis B virus in hepatomas accumulate in MHC class II-restricted T cell epitopes

Despite the extensive molecular information on serum-derived human hepatitis B viruses (HBV), liver-derived replicative HBV genomes have remained largely uninvestigated. We have examined the sequences of the entire core antigen (nucleocapsid) of liver-derived HBVs in 15 different hepatoma patients. Bona fide mutations, rather than subtype polymorphism, have been identified based on the high-frequency occurrence of structural differences from wild type at the highly evolutionarily conserved positions, instead of at the positions known to contain genetic heterogeneity among different isolates from different geographic locations. The distribution of these naturally occurring mutations of HBV core gene appears to be nonrandom and is found predominantly within three major (I, IV, and V) and four minor domains (II, III, VI, and VII). In general, domain IV mutations correlate with domain V mutations. The replicative HBV DNAs tend to accumulate a higher number of mutated core domains than the integrated HBV DNAs. At the domain level, there is no significant difference in HBV core mutation frequencies between the liver tumors and the adjacent nontumorous livers. Strikingly, domains I, III, and V coincide with three major known T cell epitopes within the core protein in acute and chronic hepatitis B patients. Furthermore, these domains coincide with HLA class II-restricted T cell epitopes, rather than with the conventional HLA class I-restricted epitopes of cytotoxic T lymphocytes. Our results support the hypothesis that HBV core antigen variants can accomplish immunoevasion via accumulated escape mutations. In addition, they also provide a potential molecular explanation for the maintenance of persistent infection of human hepatitis B virus in chronic carriers.

The mechanism of natural occurrence of two closely linked HBV precore predominant mutations

Two precore predominant mutations of human hepatitis B virus (HBV) at either nucleotide (nt) 1896 or nt 1899 often occur in combination. At nt 1896, a G to A mutation creates a TAG stop codon at codon 28 of precore protein. At nt 1899, a G to A mutation changes glycine at codon 29 to aspartic acid. To assess the effect of each individual mutation as well as any interaction between these two mutations, HBV derivatives bearing one or both precore predominant mutations have been constructed. HBV e-Ag-negative mutants bearing a TAG stop codon mutation at codon 28 uniformly replicate at least 20-fold better than mutants bearing a TGA stop codon at the same amino acid position, irrespective of the sequence context at nt 1899. A single mutation at nt 1899, changing the wild-type G to a pyrimidine (T or C) is deleterious to viral RNA encapsidation and DNA replication. Our results explain in part why only a purine (G or A) at nt 1899, never a pyrimidine, is observed in natural HBV genomes. The effects caused by these two closely linked mutations on viral replication are not independent of each other. The stringent selection for a highly efficient RNA encapsidation element may play a crucial role in the natural occurrence of these two closely linked precore mutations. The putative 27-amino-acid peptide resulting from the truncation of precore by the nt 1896 mutation has no apparent effect on viral replication. The preferential occurrence of the G to A mutation at nt 1896 and 1899, instead of at other nonpredominant positions, is likely to be a combined consequence of both selection and higher intrinsic mutation frequency at these positions.

Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs

The metabolism of 5,10-dideazatetrahydrofolate (DDATHF [lometrexol]) to polyglutamate derivatives by folylpoly-gamma-glutamate synthetase (FPGS) plays a central role in the activity of this compound as an antineoplastic agent. The availability of a series of DDATHF derivatives differing in structure throughout the molecule has allowed a study of the structural requirements for substrate activity with mouse liver and hog liver FPGS. Kinetics of the polyglutamation reaction in vitro have been related to the potency of these compounds as inhibitors of the growth of human CEM leukemic cells. The structure-activity relationships for enzyme from both sources were nearly identical. FPGS from both species showed a broad acceptance for structural changes in the pyridopyrimidine ring, in the phenyl group, and in the intermediate bridge region, with structural changes in these regions being reflected in changes in Km for FPGS but much more modest alterations in Vmax. The data suggested that the phenyl ring was not contributing to any pi-pi hydrophobic interactions. It appeared to function primarily in maintaining a favorable distance between the pyridopyrimidine ring and the glutamate side chain. The lowest Km values were found for DDATHF analogs in which there were small alterations at the 10 position, e.g., 5-deazatetrahydrofolate, 10-methyl-DDATHF, and 10-formyl-5-deazatetrahydrofolate; the first-order rate constants for these substrates were the highest in this series, an indication of the efficiency of polyglutamation at low substrate concentrations. After correction for the intrinsic inhibitory activity of the parent DDATHF analog as an inhibitor of the target enzyme, the first-order rate constants for FPGS were found to be predictive of the potency of tumor cell growth inhibition for most of the compounds in this structural series.